John R. Stuelpnagel - Nov 1, 2021 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role
Director
Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact
Stock symbol
TXG
Transactions as of
Nov 1, 2021
Transactions value $
-$817,567
Form type
4
Date filed
11/3/2021, 07:13 PM
Previous filing
Oct 20, 2021
Next filing
Nov 18, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Sale -$16K -100 -0.03% $160.33 362K Nov 1, 2021 Direct F1
transaction TXG Class A Common Stock Sale -$16.1K -100 -0.03% $160.75 361K Nov 1, 2021 Direct F1
transaction TXG Class A Common Stock Sale -$16.2K -100 -0.03% $161.52 361K Nov 1, 2021 Direct F1
transaction TXG Class A Common Stock Sale -$244K -1.49K -0.41% $163.10 360K Nov 1, 2021 Direct F1, F2
transaction TXG Class A Common Stock Sale -$476K -2.91K -0.81% $163.89 357K Nov 1, 2021 Direct F1, F3
transaction TXG Class A Common Stock Sale -$49.4K -300 -0.08% $164.58 357K Nov 1, 2021 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $162.50 to $163.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $163.50 to $164.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $164.55 to $164.63. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.